Core Viewpoint - Praxis Precision Medicines, Inc. has announced a proposed public offering of its common stock and prefunded warrants to certain investors, with all securities offered by the company [1] Group 1: Offering Details - The offering will include a 30-day option for underwriters to purchase additional shares up to 15% of the total shares sold at the public offering price, minus underwriting discounts and commissions [1] - The offering is being managed by TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities as joint book-running managers [2] - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing on December 23, 2024 [3] Group 2: Prospectus Information - The proposed offering will be conducted only through a preliminary prospectus supplement and the accompanying base prospectus [3] - Interested parties can obtain a copy of the preliminary prospectus from the specified financial institutions [3]

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) ("Hyperfine†or the "Company†) today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securities sold in ...

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has announced a public offering of 11 million shares at $12.00 per share, aiming to raise approximately $150 million to support its clinical development and corporate initiatives [1][2]. Group 1: Offering Details - The offering includes 11,000,000 shares of common stock priced at $12.00 each and pre-funded warrants for 1,500,000 shares at $11.999 each, with total gross proceeds expected to be around $150 million before expenses [1]. - The closing of the offering is anticipated on or about October 16, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,875,000 shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [2]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, currently in Phase 3 trials for wet AMD and expected to initiate trials for DME in early 2026 [6][8]. - The company has a history of developing four approved drugs over three decades, treating tens of thousands of patients [7].

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has initiated a public offering of $150 million in common stock to support its clinical development and corporate initiatives [1][3]. Group 1: Offering Details - The public offering consists of $150 million in shares, with an option for underwriters to purchase an additional $22.5 million within 30 days [1][2]. - J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are the joint book running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [3]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, with its lead product candidate being DURAVYU™, which is currently in Phase 3 trials [7]. - DURAVYU™ combines vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [7]. - The company has a history of developing four approved drugs over three decades, treating tens of thousands of patients [8].

Core Viewpoint - Hycroft Mining Holding Corporation has announced the exercise of the underwriters' over-allotment option in connection with its public offering of Class A Common Stock, increasing the total shares offered and expected proceeds significantly [1][2]. Offering Details - The underwriters exercised an over-allotment option to purchase an additional 3,295,076 shares at a public offering price of $6.50 per share [1]. - The initial public offering was for 23,076,924 shares, which has now been upsized to a total of 26,372,000 shares, resulting in gross proceeds of approximately $171.4 million, up from an initial estimate of $150 million [2]. - The offering is expected to close on October 14, 2025, subject to customary closing conditions [2]. Use of Proceeds - The net proceeds from the offering will be utilized to expand and accelerate exploration and drilling programs, as well as for general corporate and working capital needs, including the anticipated repayment or repurchase of existing debt obligations [4]. Company Background - Hycroft Mining Holding Corporation is a US-based gold and silver company focused on developing the Hycroft Mine, one of the largest precious metals deposits globally, located in northern Nevada [7]. - The company aims to transition the Hycroft Mine into the next phase of commercial operations for processing sulfide ore and is engaged in a robust exploration drill program to expand high-grade silver systems [7].

Core Viewpoint - Univest Securities announced the closing of a public offering for EPWK Holdings Ltd, raising approximately $8 million to support the company's growth and operations [1][3]. Group 1: Offering Details - The offering consisted of 24,242,425 units, each unit comprising one Class A ordinary share or a pre-funded warrant, along with one warrant to purchase one Class A ordinary share [2]. - The public offering price was set at $0.33 per unit, with warrants having an exercise price of $0.3465 per Class A ordinary share, exercisable for six months from the issuance date [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research development, business expansion, general working capital, and other corporate purposes [3]. Group 3: Company Background - EPWK Holdings Ltd connects businesses with talent through an innovative crowdsourcing platform, primarily serving small and medium-sized enterprises [7]. - The company was founded by Guohua Huang and operates through subsidiaries and contractual arrangements in China [7]. Group 4: Univest Securities Overview - Univest Securities, established in 1994, provides a range of financial services including investment banking and has raised over $1.5 billion in capital for various issuers since 2019 [6].

Core Viewpoint - Uranium Energy Corp (UEC) is proceeding with a public offering of 15,500,000 shares at a price of $13.15 per share to accelerate the development of uranium refining and conversion in the United States [1] Group 1: Offering Details - The public offering consists of 15,500,000 shares of common stock priced at $13.15 each [1] - The underwriter has been granted a 30-day option to purchase an additional 2,325,000 shares [1]

Core Points - Outcrop Silver & Gold Corporation has successfully closed a public offering of 65,780,000 units at a price of $0.35 per unit, raising approximately $23.02 million [1][3] - Each unit consists of one common share and one-half of a common share purchase warrant, with warrants exercisable at $0.55 for 24 months [2] - The net proceeds will be allocated for exploration and drilling at the Santa Ana project and for general working capital [3] Offering Details - The offering was led by BMO Capital Markets and Research Capital Corporation, with a total cash commission of 6.0% on gross proceeds, amounting to $1,381,380 [3] - Jupiter Asset Management acquired 42,857,142 units for a total of $15 million, while Eric Sprott acquired 14,285,716 units for $5 million [4] Company Overview - Outcrop Silver is focused on advancing its flagship Santa Ana high-grade silver project in Colombia, emphasizing responsible mining practices and community engagement [7][8] - The company aims to expand its mineral resources through strategic exploration initiatives, leveraging a seasoned team with extensive regional experience [8]

Core Viewpoint - CCSC Technology International Holdings Limited has successfully closed a public offering, raising approximately $7.06 million to enhance its market position and pursue strategic initiatives in Europe and Southeast Asia [1][2]. Group 1: Offering Details - The public offering included 11,766,627 Class A ordinary shares and 23,533,254 warrants, with each share sold at a price of $0.60, accompanied by two warrants [1]. - Each warrant has an exercise price of $0.72 per share, which is 120% of the public offering price, and will expire five years from the issuance date [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for strengthening branding and marketing efforts, strategic acquisitions, collaborations, and general corporate purposes [2]. Group 3: Company Overview - CCSC Technology International Holdings Limited specializes in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses, serving various industries such as industrial, automotive, robotics, medical equipment, and telecommunications [6]. - The company operates under both OEM and ODM models, catering to a diverse global customer base across more than 25 countries [6].

Core Viewpoint - CCSC Technology International Holdings Limited has announced a public offering of Class A ordinary shares and warrants, aiming to raise approximately $7.06 million to enhance its market position and pursue strategic initiatives in Europe and Southeast Asia [1][2]. Group 1: Offering Details - The offering includes 11,766,627 Class A ordinary shares and 23,533,254 warrants, with a combined public offering price of $0.60 per share and accompanying warrants [1]. - Each warrant has an exercise price of $0.72 per share, which is 120% of the public offering price, and will expire five years from the issuance date [1]. - The offering is expected to close on or about October 2, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for strengthening branding and marketing efforts, strategic acquisitions, collaborations, and general corporate purposes [2]. Group 3: Company Overview - CCSC Technology International Holdings Limited specializes in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses, serving various industries such as industrial, automotive, robotics, and telecommunications [6]. - The company operates under both OEM and ODM models, catering to a diverse global customer base across more than 25 countries [6].